BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22418445)

  • 1. Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience.
    Korkusuz H; Knau L; Kromen W; Huebner F; Hammerstingl R; Lindemayr S; Bihrer V; Piiper A; Vogl TJ
    Cancer Imaging; 2012 Mar; 12(1):72-8. PubMed ID: 22418445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.
    Korkusuz H; Knau LL; Kromen W; Bihrer V; Keese D; Piiper A; Vogl TJ
    J Magn Reson Imaging; 2012 Jun; 35(6):1397-402. PubMed ID: 22267126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.
    Okada M; Imai Y; Kim T; Kogita S; Takamura M; Kumano S; Onishi H; Hori M; Fukuda K; Hayashi N; Wakasa K; Sakamoto M; Murakami T
    J Magn Reson Imaging; 2010 Oct; 32(4):903-13. PubMed ID: 20882621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.
    Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Hübner F; Waidmann O; Zeuzem S; Korf HW; Terfort A; Gelperina S; Vogl TJ; Kreuter J; Piiper A
    J Control Release; 2015 Feb; 199():63-71. PubMed ID: 25499552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.
    Brunsing RL; Chen DH; Schlein A; Wolfson T; Gamst A; Mamidipalli A; Vietti Violi N; Marks RM; Taouli B; Loomba R; Kono Y; Sirlin CB
    Radiol Imaging Cancer; 2019 Nov; 1(2):e190010. PubMed ID: 33778680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.
    Ichikawa S; Motosugi U; Morisaka H; Kozaka K; Goshima S; Ichikawa T
    Magn Reson Med Sci; 2021 Mar; 20(1):47-59. PubMed ID: 32101818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation.
    Fischer MA; Raptis DA; Donati OF; Hunziker R; Schade E; Sotiropoulos GC; McCall J; Bartlett A; Bachellier P; Frilling A; Breitenstein S; Clavien PA; Alkadhi H; Patak MA
    Eur J Radiol; 2015 Oct; 84(10):1879-87. PubMed ID: 26194029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.
    Sugimoto K; Moriyasu F; Shiraishi J; Saito K; Taira J; Saguchi T; Imai Y
    Eur Radiol; 2012 Jun; 22(6):1205-13. PubMed ID: 22270142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.
    Kim SY; Wu EH; Park SH; Wang ZJ; Hope TA; Yee J; Zhao LQ; Chang WC; Yeh BM
    Abdom Radiol (NY); 2016 Aug; 41(8):1522-31. PubMed ID: 26971341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.
    Tan CH; Chou SC; Inmutto N; Ma K; Sheng R; Shi Y; Zhou Z; Yamada A; Tateishi R
    Korean J Radiol; 2022 Jul; 23(7):697-719. PubMed ID: 35555884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fat containing HCC: findings on CT and MRI including serial contrast-enhanced imaging.
    Balci NC; Befeler AS; Bieneman BK; Fattahi R; Saglam S; Havlioglu N
    Acad Radiol; 2009 Aug; 16(8):963-8. PubMed ID: 19386514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
    Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
    AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
    Motosugi U; Bannas P; Sano K; Reeder SB
    J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.